Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 101, Issue 2, Pages 182-184Publisher
WILEY
DOI: 10.1002/cpt.441
Keywords
-
Categories
Funding
- NIH CounterACT grant [U01-NS083460]
Ask authors/readers for more resources
Cannabis-derived cannabinoids such as cannabidiol (CBD) have anticonvulsant properties. Recently, there has been an emerging interest in the use of CBD-enriched products for treatment of drug-resistant epilepsy. Some pilot trials of CBD have proved beneficial for refractory epilepsy, but its efficacy is yet to be confirmed by standard placebo-controlled trials. However, the mechanisms underlying the seizure protection efficacy claims of CBD remain unclear. This review briefly describes the clinical utility of CBD in the treatment of refractory epilepsy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available